Satellos Forms Clinical Advisory Board for SAT-3247 Development in Duchenne Muscular Dystrophy Trials
Satellos Bioscience Inc., a Toronto-based biotech firm specializing in the development of small molecule therapeutics for muscle diseases, announced the establishment of a Clinical Advisory Board. This board, composed of eminent clinical research leaders and experts in genetic muscle disorders including Duchenne muscular dystrophy (DMD), marks a pivotal step in the company’s progression towards becoming a clinical-stage drug development entity.
Frank Gleeson, Co-founder and CEO of Satellos, emphasized the significance of this development. He expressed pride and excitement in bringing together global experts dedicated to the clinical advancement of novel therapeutic solutions for degenerative muscle diseases. The Clinical Advisory Board's formation is anticipated to bolster the advancement of Satellos' leading drug candidate, SAT-3247, optimizing its potential to revolutionize the treatment landscape for DMD and other serious muscle diseases.
The Clinical Advisory Board includes the following distinguished members:
- Jordan Dubow, M.D.: Serving as the Chair of the CAB and Chief Medical Advisor for Satellos, Dubow brings extensive experience in the biopharmaceutical sector, having significantly contributed to 16 new drug applications (NDAs), inclusive of DMD therapeutics.
- Ronald Cohn, M.D., Ph.D.: President and CEO at the Hospital for Sick Children, Cohn is a renowned clinician scientist focused on pediatric disease diagnostics and treatment, particularly muscular dystrophies, employing genome editing technologies like CRISPR.
- Richard Finkel, M.D.: As Director at the Center for Experimental Neurotherapeutics, St. Jude Children’s Research Hospital, Finkel is recognized for his role in pivotal clinical trials for neuromuscular diseases, including the first approved therapy for spinal muscular atrophy.
- Nicholas Johnson, M.D.: Director of the Center for Inherited Myology Research at VCU Health, Johnson conducts therapeutic trials focused on inherited nerve and muscle disorders and contributes substantially to laboratory research on genetic muscle disorders.
- Hanns Lochmüller, M.D., Ph.D.: A Senior Scientist at the Children’s Hospital of Eastern Ontario Research Institute, Lochmüller focuses on clinical research and care for rare genetic neuromuscular disorders, with significant contributions to molecular therapies.
- Francesco Muntoni, M.D.: Director of the Dubowitz Neuromuscular Centre, Muntoni’s research has led to FDA approval of two DMD therapies. He focuses on developing new treatments for pediatric neuromuscular disorders.
- Perry Shieh, M.D., Ph.D.: A Professor of Neurology at UCLA, Shieh’s primary clinical interests include DMD and myotonic dystrophy, participating in multiple clinical trials for these disorders.
About SAT-3247
SAT-3247 is an oral small molecule drug developed to address the root cause of muscle degeneration in diseases like Duchenne muscular dystrophy. It operates by restoring impaired muscle regeneration due to the lack of functional dystrophin through a novel mechanism of action. SAT-3247 is designed to be effective regardless of a patient’s genetic mutation or ambulatory status and aims to complement existing therapies aimed at restoring dystrophin production.
About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is an inherited disorder stemming from mutations in the dystrophin gene, leading to compromised muscle repair and regeneration. Satellos has developed SAT-3247 to regulate a dystrophin-independent pathway to improve muscle function, offering a potential standalone therapeutic approach.
About Satellos Bioscience Inc.
Satellos Bioscience Inc. is a publicly traded biotechnology firm dedicated to the development of innovative treatments for degenerative muscle diseases. Utilizing its proprietary MyoReGenX™ platform, Satellos aims to identify muscle diseases treatable through the modulation of muscle stem cell polarity, fostering muscle repair and regeneration. The company's leading program involves developing SAT-3247, an oral small molecule drug for DMD. Satellos is headquartered in Toronto, Ontario.
The formation of the Clinical Advisory Board and the development of SAT-3247 underscores Satellos’ commitment to pioneering advancements in the treatment of muscle degenerative diseases, potentially transforming patient outcomes in the future.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
